Arrowhead Pharmaceuticals, Inc.

LSE:0HI3 Stock Report

Market Cap: US$2.4b

Arrowhead Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?


Recent Insider Transactions

LSE:0HI3 Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
18 Dec 24SellUS$567,486Christopher AnzaloneIndividual26,712US$22.12
18 Apr 24BuyUS$62,176Hongbo LuIndividual2,400US$28.00
01 Apr 24SellUS$168,180James HamiltonIndividual6,000US$28.03
20 Mar 24BuyUS$82,990Hongbo LuIndividual3,000US$28.00
06 Mar 24SellUS$1,407,600Kenneth MyszkowskiIndividual40,000US$35.19

Insider Trading Volume

Insider Buying: 0HI3 insiders have only sold shares in the past 3 months.


Ownership Breakdown

What is the ownership structure of 0HI3?
Owner TypeNumber of SharesOwnership Percentage
State or Government31,6150.0254%
Individual Insiders5,002,7174.02%
Hedge Funds8,888,8887.14%
General Public21,488,21017.3%
Institutions89,023,01271.5%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 15.8%.


Top Shareholders

Top 25 shareholders own 67.56% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
12.7%
BlackRock, Inc.
15,835,912US$310.9m0.97%no data
9.83%
The Vanguard Group, Inc.
12,229,055US$240.1m0.12%no data
7.14%
Avoro Capital Advisors LLC
8,888,888US$174.5m0%2.44%
5.11%
State Street Global Advisors, Inc.
6,354,331US$124.7m8.85%no data
4.88%
FMR LLC
6,067,062US$119.1m-10.9%0.01%
3.93%
Slate Path Capital LP
4,885,000US$95.9m18%1.54%
2.99%
Christopher Anzalone
3,715,048US$72.9m0%no data
2.93%
T. Rowe Price Group, Inc.
3,651,071US$71.7m38.6%0.01%
2.38%
Geode Capital Management, LLC
2,964,119US$58.2m0.89%no data
2.09%
UBS Asset Management AG
2,595,761US$51.0m-1.62%no data
1.98%
Artal Group S.A.
2,458,778US$48.3m-22.9%1.44%
1.49%
JP Morgan Asset Management
1,848,679US$36.3m-0.45%no data
1.27%
Norges Bank Investment Management
1,585,320US$31.1m0%no data
1.15%
Morgan Stanley, Investment Banking and Brokerage Investments
1,432,016US$28.1m-12.2%no data
1.07%
Northern Trust Global Investments
1,332,765US$26.2m0.76%no data
0.95%
Goldman Sachs Group, Investment Banking and Securities Investments
1,178,564US$23.1m4.95%0.01%
0.95%
Citadel Advisors LLC
1,177,577US$23.1m24.2%0.03%
0.81%
Charles Schwab Investment Management, Inc.
1,006,935US$19.8m1.26%no data
0.7%
Woodline Partners LP
865,794US$17.0m5.39%0.15%
0.69%
BNY Asset Management
858,222US$16.8m-20.3%no data
0.66%
Western Financial Corporation
820,239US$16.1m0%8.69%
0.64%
Aquilo Capital Management, LLC
795,813US$15.6m-12.4%23.09%
0.52%
Millennium Management LLC
645,604US$12.7m22%0.01%
0.37%
Jane Street Group, LLC, Asset Management Arm
463,880US$9.1m-33.4%0.01%
0.33%
Bank of America Corporation, Asset Management Arm
409,297US$8.0m13.1%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 12:56
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2024/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Arrowhead Pharmaceuticals, Inc. is covered by 29 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research
Ying HuangBarclays
Jason Matthew GerberryBofA Global Research